https://the483.com/china-ai-distillation-theft-crackdown/ The 483 en 2026-04-24T14:38:16.000Z Prosecute China for AI Model Theft, Congress Tells State Department https://the483.com/regeneron-otarmeni-mfn-deal/ The 483 en 2026-04-24T13:49:13.545Z FDA Cleared Regeneron's Otarmeni; Last Big Pharma Signs MFN Deal https://the483.com/secure-data-act-illinois-bipa-preemption/ The 483 en 2026-04-24T03:11:32.000Z Filed: H.R. 8413 Could Preempt Illinois BIPA, California's Delete Act https://the483.com/amneal-kashiv-1b-biosimilar-deal/ The 483 en 2026-04-24T01:39:26.000Z Bought for $1.1B: Amneal Gets Kashiv and Its $56B Biosimilar Pipeline https://the483.com/amneal-biosimilar-375m-deal/ The 483 en 2026-04-24T00:47:20.000Z Amneal Buys Biosimilar Maker for $375M Upfront https://the483.com/regeneron-otarmeni-free-gene-therapy-hearing/ The 483 en 2026-04-23T23:21:02.000Z FDA Cleared Regeneron's $0 Gene Therapy for Rare Hearing Loss https://the483.com/regeneron-otarmeni-hearing-loss/ The 483 en 2026-04-23T22:19:23.000Z FDA Clears Regeneron's Otarmeni, First Gene Therapy for Inherited Hearing Loss https://the483.com/abbvie-14b-durham-campus/ The 483 en 2026-04-23T17:35:37.000Z AbbVie Builds $1.4B Durham Campus, First in North Carolina https://the483.com/new-life-pharma-glp1-inspection-warning/ The 483 en 2026-04-23T16:39:00.000Z FDA Warns New Life Pharma After GLP-1 Inspection Refusal https://the483.com/sqm-sec-fcpa-probe-resumed/ The 483 en 2026-04-23T15:40:00.000Z Fined $30.5M in 2017, SQM Now Faces Resumed SEC FCPA Probe https://the483.com/merck-google-1b-ai-deal/ The 483 en 2026-04-23T14:51:34.000Z Cut $1B Google Cloud Deal, Merck Targets HCP Engagement https://the483.com/ionis-zilganersen-alexander-disease-fda/ The 483 en 2026-04-23T12:29:03.000Z Ionis Filed Zilganersen for Sept. 22 FDA Decision; First AxD Drug https://the483.com/amneal-kashiv-1b-biosimilar-buyout/ The 483 en 2026-04-23T03:11:09.000Z Buys Kashiv for $1.1B, Amneal Eyes $200B Biosimilar Market https://the483.com/forager-repay-1b-takeover/ The 483 en 2026-04-23T01:38:59.000Z Forager Bids $1B for Repay at 75% Premium https://the483.com/lilly-kelonia-7b-gene-delivery/ The 483 en 2026-04-23T00:51:19.000Z Paid $7B for Kelonia, Lilly Bets on In Vivo Gene Delivery https://the483.com/smartmatic-fcpa-indictment-dismissal/ The 483 en 2026-04-22T22:19:55.000Z Smartmatic Fights First Corporate FCPA Indictment Since 2010 https://the483.com/pancreatic-cancer-herceptin-1998-turning-point/ The 483 en 2026-04-22T18:29:27.000Z Compared to Herceptin's 1998 Approval: Pancreatic Cancer Hits a Turning Point https://the483.com/novartis-abelacimab-cuts-cancer-trials/ The 483 en 2026-04-22T17:25:29.000Z Cut 2 Abelacimab Cancer Trials, Novartis Bets $925M on Afib https://the483.com/apollo-mckesson-mms-minority-stake/ The 483 en 2026-04-22T16:28:50.000Z Paid $1.25B, Apollo Takes 13% of McKesson's Surgical Unit https://the483.com/kyverna-miv-cel-sps-car-t-fda/ The 483 en 2026-04-22T15:33:19.000Z Kyverna Sweeps All KYSA-8 Endpoints: 46% SPS Improvement, FDA Filing Next